Healthcare Industry News: Isis Pharmaceuticals
News Release - August 9, 2006
ADVENTRX Announces Appointment of General CounselSAN DIEGO, Aug. 9 (HSMN NewsFeed) -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) announced today that Patrick Keran has been appointed to the newly created position of general counsel.
Prior to ADVENTRX, Mr. Keran served as associate general counsel for Isis Pharmaceuticals, Inc. Before that, Mr. Keran practiced corporate and commercial law at the law firms Heller Ehrman, LLP and Brobeck, Phleger & Harrison LLP. He received his law degree from the University of California, Berkeley and completed his undergraduate degree at the University of California, San Diego.
"We are pleased to welcome Patrick to the ADVENTRX team and believe he will prove an important asset at this key time in our corporate development," said Evan M. Levine, ADVENTRX president and CEO.
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious disease that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at www.adventrx.com.
Forward Looking Statement
This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last annual report on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions to forward-looking statements to reflect events or circumstances which occur after the date hereof.
Source: ADVENTRX Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.